Drugs Made in America Acquisition Corp.

Drugs Made In America Acquisition, a blank check company focusing on the U.S. pharmaceutical sector.

The Fort Lauderdale, Florida-based company aims to raise $500 million by offering 50 million units at $10 each. Each unit will include one share of common stock and rights to one-tenth of a share. If the offering goes as planned, the company would achieve a market valuation of $706 million.

Drugs Made In America Acquisition is led by CEO and Executive Chair Lynn Stockwell, who is also the founder and Chair of Bright Green (Nasdaq: BGXX), and CFO Glenn Worman, a partner at SeatonHill Partners and CFO of Insight Acquisition (NYSE: INAQ). The company intends to target a pharmaceutical business within the United States.

Founded in 2024, Drugs Made In America Acquisition is based in Fort Lauderdale, Florida, and plans to list on the Nasdaq under the symbol DMAAU. EF Hutton will serve as the sole bookrunner for the deal.